News - Pharmaceuticals
‘Leadership demands both conviction and humility’, says Novo Nordisk GM

With more than three decades in biopharma behind him, Michael Azrak, General Manager of Novo Nordisk Oceania, has stepped into a leadership role at a time when the very conditions of leadership are increasingly negotiated in real time.
In this episode of Health Industry Hub‘s Senior Leadership Series, Azrak reflects on what it means to lead a healthcare organisation through a period where scale, scrutiny, and expectations are expanding in magnitude and intensity. He unpacks how ‘solving problems at scale’ becomes not just an operational challenge, but a defining leadership posture.
Against this backdrop, Azrak explores how Novo Nordisk is co-creating solutions to reshape the trust narrative across patients, clinicians, and government stakeholders, while also navigating the dual demand of global consistency and local authenticity.
In closing, he offers perspective for the next generation of leaders navigating the ‘decade of disorientation’, where the focus is less about mastering control and more about “conviction and humility” within the absence of certainty.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More